Ainos Inc

Ainos Inc(AIMD)股票分析

$0.960

-0.107 (-11.11%)收盤時

Loading chart…
最高
1.090
開盤
1.090
成交量加權均價
1.00
成交量
36.89K
市值
5.50M
最低
0.955
成交金額
36.95K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.

AI 分析 of Ainos Inc (AIMD)

賣出

Ainos Inc is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $1.21, and the RSI is at 27.229, indicating oversold conditions but also suggesting continued weakness. Additionally, the forward P/E ratio is 13.9082, which is high given the company's declining revenues and increasing losses, with a 1-year change of -69.29%.

估值指標

Ainos Inc(AIMD)目前預期本益比為 13.91,5 年平均預期本益比為 2.23。

預期本益比

嚴重高估
5 年均值 P/E
2.23
目前P/E
13.91
高估
7.31
低估
-2.84

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 AIMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%AIMD

$3.22

情境價格

基

基準

基準 · 50%AIMD

$2.84

情境價格

悲

悲觀

悲觀 · 25%AIMD

$2.25

情境價格

事件時間軸

2026-09-30 (ET)

10:00:00

Ainos Completes VELDONA Data Delivery, Triggers $600,000 Initial Payment

2026-09-29 (ET)

08:30:00

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE

2026-09-28 (ET)

09:00:00

Ainos VELDONA License Agreement Initial Fee of $600,000

2026-09-24 (ET)

09:00:00

Ainos Enters VELDONA License Agreement with BioPhoenix, Potential Value of $10M

2026-09-14 (ET)

08:30:00

Ainos Launches Second-Gen AI Nose Platform, Secures Initial Orders

資訊

AIMD 常見問題 —— 由 Alphio AI 解答

Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ainos Inc is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $1.21, and the RSI is at 27.229, indicating oversold conditions but also suggesting continued weakness. Additionally, the forward P/E ratio is 13.9082, which is high given the company's declining revenues and increasing losses, with a 1-year change of -69.29%.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易